← Back to Search

FDG PET/CT for Non-Small Cell Lung Cancer

N/A

Waitlist Available

Led By Daniel Pryma, MD

Research Sponsored by Abramson Cancer Center of the University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adult patients, at least 18 years of age

Patients with NSCLC diagnosis who have been referred for a clinical FDG PET/CT staging scan as part of their standard of care

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trialstudied how imaging works to diagnose lung cancer in the chest, to improve accuracy.

Who is the study for?

This trial is for adults over 18 with a diagnosis of non-small cell lung cancer (NSCLC) who need an FDG PET/CT scan as part of their usual care. They must understand the study's research nature and agree to it in writing. It's not for those who can't handle extra imaging time, economically disadvantaged individuals, children, neonates, prisoners, or mentally disabled persons.Check my eligibility

What is being tested?

The study is looking at how different ways of taking pictures and processing them affect the accuracy of FDG PET/CT scans used to figure out if NSCLC has spread to lymph nodes in the chest area. This is a forward-looking study that tracks participants over time.See study design

What are the potential side effects?

Since this trial involves standard FDG PET/CT imaging procedures, side effects may include discomfort from lying still during scanning and potential reactions to contrast agents like mild allergic symptoms or temporary nausea.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have NSCLC and am scheduled for a PET/CT scan.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Adverse Events

Trial Design

1Treatment groups

Experimental Treatment

Group I: PET imagingExperimental Treatment1 Intervention

PET imaging

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

FDG PET/CT

2014

N/A

~170

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor

359 Previous Clinical Trials

105,065 Total Patients Enrolled

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,665 Total Patients Enrolled

Daniel Pryma, MDPrincipal InvestigatorAbramson Cancer Center at Penn Medicine

3 Previous Clinical Trials

104 Total Patients Enrolled

Media Library

FDG PET/CT Clinical Trial Eligibility Overview. Trial Name: NCT02738398 — N/A

Non-Small Cell Lung Cancer Research Study Groups: PET imaging

Non-Small Cell Lung Cancer Clinical Trial 2023: FDG PET/CT Highlights & Side Effects. Trial Name: NCT02738398 — N/A

FDG PET/CT 2023 Treatment Timeline for Medical Study. Trial Name: NCT02738398 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there any opportunity for enrollment in this clinical investigation?

"As is evident on clinicaltrials.gov, this specific medical study is no longer registering patients. It was first available to the public via the website on April 1st 2016 and its information most recently changed on November 11th 2022. Notwithstanding, there are 1769 other ongoing trials that remain open for enrollment at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

FDG PET/CT in Lung Cancer Staging

2016. "FDG PET/CT in Lung Cancer Staging". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02738398.

All > Lung Cancer Philadelphia